Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21 (PlGF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01387776|
Recruitment Status : Terminated (The technique has been approved and validated)
First Posted : July 6, 2011
Last Update Posted : July 28, 2015
This is a study for the evaluation of the benefits of 1 st Trimester risk markers in detecting Early Onset Pre-eclampsia and the use of the Placental Growth factor(PIGF) as a potential marker for Trisomy 21 and other aneuploidies.
Aim of this prospective nonprofit study is to analyze the benefits of early onset pre eclampsia risk assessment in the 1st trimester (measuring biochemical markers [PIGF], blood pressure and Doppler ultrasound), and how the results can permit to modify or influence the course of the preeclampsia during the pregnancy. The investigators will also evaluate the potential use of the PIGF as a marker to improve the prenatal screening with the currently used nuchal translucency, serum Pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (fBhCG) parameters.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||370 participants|
|Official Title:||Study for the Evaluation of the Benefits of 1 st Trimester Risk Markers in Detecting Early Onset Pre-eclampsia and the Use of the Placental Growth Factor (PlGF) as a Potential Marker for Trisomy 21 and Other Aneuploidies|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
- levels of Placental Protein 13 (PP13) , PIGF, PAPP-A, PIBF [ Time Frame: 6-13.6 wks gestation ]levels of PP13, PIGF, PAPP-A will de considered in association with Doppler ultrasound and standardised blood pressure measurements to see if they can be used as early risk markers in patients having a delivery before 34 weeks gestation
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01387776
|Montreal, Quebec, Canada, H4P2S4|
|Principal Investigator:||Robert Hemmings, MD||Clinique OVO|
|Study Director:||Bernard Couturier, MD||Clinique OVO|
|Study Chair:||Dominique Berube, PhD||Clinique OVO|